The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Astellas, Daiichi Sankyo, Johnson & Johnson, Kura Oncology and Syndax, and has been supported through educational grants from Bristol Myers Squibb and the Hippocrate Conference Institute, an association of the Servier Group. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View aml content recommended for you
During the 3rd NCRI AML Academy, the AML Hub was pleased to speak with David Taussig, The Royal Marsden Hospital, London, UK. We asked, Should Venetoclax based induction regimens be considered standard of care for 60+ adults?
Should Venetoclax based induction regimens be considered SOC for 60+ adults?
Taussig begins by highlighting that for adults not fit for intensive chemotherapy, evidence favors the use of venetoclax + azatadine. He goes on to outline AML subtypes that can benefit from venetoclax regimens in fit patients, discussing FLT-3 mutations and the BELLINI trial.
Your opinion matters
Approximately what proportion of your patients with FLT3-mutations also have NPM1 and DNMT3A co-mutations?